Anti-Aβ Oligomer IgG and Surface Sialic Acid in Intravenous Immunoglobulin: Measurement and Correlation with Clinical Outcomes in Alzheimer’s Disease Treatment

Hyewon Kwon¹, Amanda C. Crisostomo²*, Hayley Marie Smalls²*, John M. Finke²*

¹ Department of Medicinal Chemistry, University of Washington, Seattle, Washington, United States of America, ² Division of Science and Mathematics, University of Washington, Tacoma, Washington, United States of America

☯ These authors contributed equally to this work.
* jfinke@u.washington.edu

Abstract

The fraction of IgG antibodies with anti-oligomeric Aβ affinity and surface sialic acid was compared between Octagam and Gammagard intravenous immunoglobulin (IVIG) using two complementary surface plasmon resonance methods. These comparisons were performed to identify if an elevated fraction existed in Gammagard, which reported small putative benefits in a recent Phase III clinical trial for Alzheimer’s Disease. The fraction of anti-oligomeric Aβ IgG was found to be higher in Octagam, for which no cognitive benefits were reported. The fraction and location of surface-accessible sialic acid in the Fab domain was found to be similar between Gammagard and Octagam. These findings indicate that anti-oligomeric Aβ IgG and total surface sialic acid alone cannot account for reported clinical differences in the two IVIG products. A combined analysis of sialic acid in anti-oligomeric Aβ IgG did reveal a notable finding that this subgroup exhibited a high degree of surface sialic acid lacking the conventional α2,6 linkage. These results demonstrate that the IVIG antibodies used to engage oligomeric Aβ in both Gammagard and Octagam clinical trials did not possess α2,6-linked surface sialic acid at the time of administration. Anti-oligomeric Aβ IgG with α2,6 linkages remains untested as an AD treatment.

Introduction

Alzheimer’s Disease (AD) cases and associated health care costs are growing at a faster rate than most other diseases due to an aging population and lack of effective treatment [1]. Based on success in early pre-clinical studies, a number of recent antibody treatments offered hope for AD patients [2–9]. Unfortunately, none of these treatments met their primary endpoints in Phase II and III clinical trials [2–5]. While disappointing, these results do provide an opportunity to learn what is missing and how newer formulations might yield success. Given that
multiple antibodies have now been tested in AD patients, one can compare properties between the antibody treatments which reported small benefits from those with no cognitive benefit [2–5]. Also, some antibody drugs failed AD clinical trials despite their success in treating other diseases [2–5]. This class of AD drug offers a unique opportunity to determine why their biological activity did not improve AD patient outcomes.

Due to its complex polyclonal nature, intravenous immunoglobulin (IVIG) is an AD drug candidate that provides a system in which multiple properties can be investigated. Until recently, IVIG was a leading candidate for AD treatment based on small early trials that indicated a possible reduction of AD progression [6,7,10,11]. Octagam (OCT) and Gammagard (GG) are the most rigorously tested IVIG products for AD treatment [2,3,12]. Two Phase II trials with Octagam and a Phase III trial with Gammagard have been completed [2,3,12]. A Phase III trial of a third IVIG product, Flebogamma (Grifols), is currently underway but results are not available [13].

A biochemical analysis and comparison of Octagam and Gammagard is warranted at this time because slightly different outcomes are reported from their clinical trials. Octagam lacked any clinical efficacy while Gammagard was reported to slow AD progression in the moderate AD and ApoE4 carrier subgroups [2,3]. The effect of Gammagard was small and the statistical significance was marginal because the study was not powered for subgroup analysis. Nonetheless, biochemical differences between these Octagam and Gammagard may provide clues about how to enhance the efficacy of AD antibody therapies.

In addition, Octagam and Gammagard are both approved for use in treating a number of autoimmune disorders [14–16]. Neuroinflammation is associated with AD but its role in the pathology has not been definitively established [17]. Investigations of putative anti-inflammatory components within IVIG might reveal how the success of IVIG with autoimmune conditions can be translated into benefits for AD patients.

A number of components and properties exist in Octagam and Gammagard that one could compare. However, two general properties are logical to investigate at this stage. The first is IgG specific for Aβ soluble oligomers (OAβ). The second is the sialic acid moieties of IgG.

Interest in IVIG as an AD treatment was initially based on a significant fraction of antibodies in IVIG that bound to Aβ peptides [10,18]. An ELISA study has shown that Octagam has a higher fraction of IgG that bind the Aβ peptide than Gammagard [19]. However, this comparison has not been made using specific preparations of OAβ as the target ligand. OAβ is more causally linked to AD pathology than either the monomeric or fibrillar form of Aβ [20–22].

Also, a previous SPR study indicates that monomeric Aβ at the sensor surface is not bound by antibodies in IVIG [23]. The ELISA studies that detect natural IgG binding to monomeric Aβ consistently report a lower binding response than to OAβ [24–27]. Thus, OAβ was the preferred Aβ assembly state to capture natural IVIG antibodies in the present study.

Glycan sialic acid in IgG was also of interest because higher levels of IgG sialic acid are reported to be associated with increased anti-inflammatory activity of IVIG in select animal models and in clinical studies with patients [16,28,29]. The level of sialic acid in therapeutic antibodies has not been generally reported in the context of AD treatment. However, a component of antibodies that might reduce neuroinflammation could be beneficial in AD treatment [17]. Thus, investigation of IgG sialic acid in the present study was warranted.

For Octagam and Gammagard, we report here the relative fraction of anti-OAβ IgG (OAβ+ IgG), the fraction of surface-accessible sialic acid on IgG, the IgG domain where the surface sialic acid predominates, and the fraction of surface sialic acid in the anti-OAβ IgG subpopulation. All variables are assessed for their correlation with the putative clinical efficacy of Gammagard. The surface sialic acid of mouse monoclonal antibodies 6E10 and 4G8 are also
presented for comparison because these two anti-\(\text{A}\beta\) antibodies exhibit distinct glycan sialylation levels and localization.

All quantitative measurements were conducted using two advanced applications of Biacore Surface Plasmon Resonance (SPR). The first method was Calibration-Free Concentration Analysis (CFCA), a method that quantifies the concentration of bulk analyte in a solution under conditions where analyte association with the sensor surface is diffusion-limited \([30–33]\). The second method is a two-step method, in which IgG is bound to the sensor ligand in the first step and sialic acid is detected using \textit{Sambucus nigra} Agglutinin (SNA) or other carbohydrate-specific lectins in the second step.

While SPR label-free methods are emerging as useful research tools \([34,35]\), the two SPR methods used here are novel approaches in the quantitative measurement of OA\(\text{A}\beta\) IgG and sialylated fractions in IgG preparations. From a technical standpoint, SPR is advantageous because it minimizes complications from nonspecific background antibody interactions that have been problematic in similar studies \([24,36,37]\). The low SPR background is the result of a brief IgG binding step and chemically inert sensor surface \([23]\). Background signal that does exist is readily identified in the reference flow cell and corrected in real time.

From a scientific standpoint, the present SPR methods facilitate the direct measurement of IgG with “surface” sialic acids that are capable of direct binding with other biomolecules. For purposes of the present study, we further specify this IgG subgroup as SNA\(^+\) IgG, defined by its capacity to bind SNA lectin \([38]\). A number of prior studies have investigated total sialic acid, Fc glycan sialylation, or Fab N-glycan sialylation in IVIG using SNA lectin affinity chromatography, HPLC and/or Mass Spectrometry \([16,28,29,39–42]\). These studies have demonstrated that different sialic acid groups in IgG do not contribute equally to SNA binding \([29,39,40]\). While these experiments have provided valuable insights, important questions remain that are relevant to AD treatment. First, the endogenous SNA\(^+\) IgG fraction of IVIG has not been directly measured as this property has thus far been inferred from affinity chromatography yields \([29,39,40]\). Second, the maximum possible SNA\(^+\) IgG fraction after enzymatic sialylation has not been determined. Third, the SNA-binding subfraction of OA\(\text{A}\beta\) IgG has not been determined.

Here, SPR is used to directly measure the concentration of OA\(\text{A}\beta\) IgG subfraction, SNA\(^+\) IgG subfraction, and the combined SNA OA\(\text{A}\beta\) IgG sub-subfraction in IVIG. This study is conducted on Octagam and Gammagard, two IVIG products with different clinical outcomes in AD clinical trials. Treatment with \(\alpha\)2,6-sialyltransferase (2,6ST) and neuraminidase (NEU) are used to determine the respective maximum and minimum SNA\(^+\) IgG fraction possible after enzymatic treatment. The SNA-binding contribution from Fab sialic acids in IgG is determined directly using EndoS enzymatic treatment to remove the Fc glycan from intact IgG preparations. For comparison, these properties are also measured in anti-\(\text{A}\beta\) monoclonal antibodies \(6\text{E}10\) and \(4\text{G}8\).

This study is important because we do not fully understand the biological activity resulting from \(\text{A}\beta\)-specific IgG, sialylated IgG, and IgG sialylation at different Fab and Fc sites. While the work focuses on IVIG products used in AD treatment, the findings complement a broader range of research efforts on IVIG treatment of autoimmune diseases \([16,28,29,39–41]\). Taken together, it is hoped that these findings will help identify new formulations of therapeutic antibodies that yield better treatment outcomes for AD patients.
Materials and Methods

Materials

IVIG product 5% Octagam Lot A322B8431 (OCT) was from Octapharma (Vienna, Austria) and 10% Gammagard Liquid LE12M126AB (GG) was from Baxter (Los Angeles, CA). Monoclonal antibodies 6E10 and 4G8 were purchased from Covance. A $\beta_1$–42 peptide was purchased from Anaspec (San Jose, CA). Two lots of 4G8 were studied and are referenced as 4G8a and 4G8b. Unconjugated and biotinylated lectin Sambucus nigra agglutinin (SNA) and unconjugated Erythrina crystallgalli lectin (ECL) was obtained from Vector Laboratories (Burlingame, CA). Protein A from Staphylococcus aureus (SpA), $\alpha$-2,6 sialyltransferase from Photobacterium damsela (2,6ST), Cytidine-5'-monophospho-N-acetylneuraminic acid (CNA) and PNGase F from Chryseobacterium meningoseptica were obtained from Sigma-Aldrich (St. Louis, MO). Recombinant neuraminidase from Clostridium perfringens (NEU) was purchased from New England Biolabs (Ipswich, MA). EndoS enzyme IgGZERO was obtained from Genovis AB (Lund, Sweden). Biacore running buffer containing 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% v/v, pH 7.4 (HBS-EP) was obtained from a 10X stock (GE Life Sciences).

IgG Enzyme Treatments

The fraction of SNA$^+$ IgG was increased to its maximal level using $\alpha 2,6$ST treatment consisting of 5 $\mu$L IgG solution containing 5 $\mu$g (33 pmol) mAb or 50–500 $\mu$g (0.3–3.3 nmol) IVIG, 5 $\mu$L of 1 M Tris pH 8 reaction buffer, 5 $\mu$L of 15 mM CNA (75 nmol), and 34 $\mu$L water. Sialic acid was removed from IgG antibodies using NEU treatment consisting of a 5 $\mu$L IgG solution containing either 5 $\mu$g mAb (33 pmol) or 50–500 $\mu$g (0.3–3.3 nmol) IVIG, 5 $\mu$L 10X reaction buffer (500 mM citrate, pH 6), 3 $\mu$L NEU (150 Units), and 37 $\mu$L water. Fc glycans were removed from IgG antibodies using EndoS treatment consisting of a 4 $\mu$L solution containing either 4 $\mu$g (33 pmol) mAb or 4–150 $\mu$g (0.3–1.2 nmol) IVIG, 32 $\mu$L phosphate buffered saline pH 7.4 (PBS), and 4 $\mu$L IgGZERO containing 80 Units of EndoS enzyme.

All N-linked glycans were removed from denatured IgG using a two-step procedure. The first step involved complete denaturation of 4 $\mu$g mAb or 40 $\mu$g IVIG with 44 $\mu$L of 0.2% SDS, 100 mM $\beta$-mercaptoethanol, 50 mM phosphate, pH 7.5 for 100°C. The second step involved addition of 4 $\mu$L of either 15% Triton X-100 or 4 $\mu$L 10% NP-40 followed by 500 mU (Sigma Units) of PNGase F.

All enzyme treatments involved incubation at 37°C for a minimum of 3 hours, with overnight incubation if possible. After enzymatic treatment, the IgG were dialyzed into HBS-EP Biacore running buffer and studied within 24 hours after removal from HBS-EP dialysis.

Aβ Oligomer Preparation

Aβ$_{1–42}$ oligomers (OAβ) were produced at high concentration to produce high density SPR sensor chips suitable for CFCA. Briefly, disaggregation of purchased Aβ$_{1–42}$ was ensured by dissolution in 50:50 trifluoroacetic acid (TFA):hexafluoroisopropanol (HFIP) at a 1 mg:1 ml peptide:solvent ratio, bath sonicated for 1 h at room temperature, and evaporated to dryness with a gentle stream of Argon gas [43]. The disaggregated Aβ$_{1–42}$ was resuspended at 20 mg/ml in dimethylsulfoxide (DMSO) and diluted 1/40 with a solution of 100 mM phosphate and 100 mM NaCl, pH 7.4, resulting in an expected concentration of 114 $\mu$M Aβ$_{1–42}$ [44]. This solution was centrifuged at 14,000 g for 10 min and filtered through a 10,000 MWCO Amicon filter. The soluble concentration in this preparation was 104 $\mu$M, determined quantitatively using the extinction coefficient of tyrosine 10 [45]. This preparation produced a high
concentration of oligomers that reached a maximal concentration after 2–3 weeks at room temperature, at which point > 95% of monomers had reacted into an assembly state. While some loss into insoluble aggregates did occur over a period of months, the soluble oligomer concentration remained high at > 50% of total Aβ_{1-42} if the sample was left unperturbed.

It is acknowledged that soluble oligomer shapes, sizes and molecular conformations can vary with preparation conditions [46–52]. In some studies, considerable effort has been devoted to producing a desired oligomer state at high purity [50]. For the present CFCA experiments, the objective is to produce and immobilize enough high-affinity antigenic oligomers so that IgG binds the sensor chip under mass transport limited conditions [30]. If these conditions are established, complications from any immobilized low-affinity oligomer states are minimal because they do not contribute significantly to binding IgG during CFCA [31].

**SPR Sensor Chip Preparation and Regeneration**

All SPR chip preparation and subsequent studies were performed using either a Biacore T100 or T200 system using Series S CM5 sensor chips (GE Healthcare). To ensure a representative background subtraction, the sample flow cell containing immobilized ligand was always placed immediately after a reference flow cell with no ligand. CM5 carboxyl group activation was performed using 7 min of a 1:1 mix of 50 mM N-hydroxysuccinimide (NHS) and 0.2 M N-ethyl-N-dimethylaminopropylcarbodiimide (EDC). After ligand immobilization, remaining activated groups were capped using 1.0 M ethanolamine (pH 8.5) for 7 min. The immobilization reaction was also performed in the reference cell but with no ligand added.

For SpA flow cells, immobilization of 3649 RU was achieved using 0.1 mg/ml (2.3 μM) SpA in 10 mM sodium acetate pH 4.5 with an automated software routine (target 3500 RU). For SNA flow cells, immobilization of 8906 RU was achieved using 0.2 mg/ml (1.4 μM) SNA in 10 mM sodium acetate pH 4 with an automated software routine (target 12,000 RU). For OAβ flow cells, OAβ described in Aβ Oligomer Preparation was first centrifuged at 12000xg, supernatant dialyzed into 10 mM acetate pH 4, and re-centrifuged immediately prior to a 2 hour immobilization at 5 μL/min. This procedure produced 3266 of initially immobilized “native” OAβ. To facilitate routine SDS regeneration of the OAβ sensor chip with high affinity antibodies, the native OAβ was treated exhaustively with 0.5% SDS regeneration buffer resulting in 2305 RU of “SDS-resistant” OAβ. This SDS-resistant OAβ proved to be highly stable in repeated SDS regenerations from multiple IgG binding experiments.

After each IgG binding measurement, flow cell regeneration was performed using two 20 s pulses of 10 mM glycine pH 1.5 for immobilized SpA and two 20 s pulses of 10 mM HCl for immobilized SNA. Flow cells containing immobilized OAβ were regenerated with three 30 s pulses of 0.5% SDS after IVIG binding and regenerated with eight 30 s pulses plus three 60 s pulses of 0.5% after 6E10 or 4G8 binding.

**Calibration-Free Concentration Analysis**

CFCA was performed using two sequential injections of IgG at different flow rates, 5 and 100 μl/min, and the association slope measured for 30 s under each flow rate. In general, only the middle time points of association period (5–25 s) were used in determining the slope to avoid signal artifacts at the start and end of the injection period. Representative CFCA measurements and fitted linear slopes are shown for mAb 4G8a on the SNA sensor chip (Fig. 1A) and on the OAβ sensor chip (Fig. 1B).

Using CFCA, the concentration of analyte in bulk solution [A_{bulk}] with affinity for the immobilized ligand can be determined using Eq. 1 using two SPR association slopes (RU/s), m₁
for low flow and \( m_2 \) for high flow \([30,33,34]\).

\[
[A_{\text{ bulk}}] = \left[ \frac{1.47 \cdot x}{G \cdot MW} \right] \left[ \frac{D^2}{h^2 B} \right]^{1/3} \left[ \frac{1}{F_1} - \frac{1}{F_2} \right] \frac{1}{m_1} \frac{1}{m_2}
\]  

(1)

All variables in Eq. 1 other than \( m_1 \) and \( m_2 \) are known for a given experiment. \( G \) is the SPR response factor for sensor surface (10^6 RU m^2/g for CM5 sensor chips), \( MW \) is the molecular weight of the analyte (150,000 g/mol for IgG), \( D \) is the diffusion constant of the analyte (3.99 \( \times\) \( 10^{-11} \) m^2/s for IgG), \( h \) is the height of the flow cell (4.0 \( \times\) \( 10^{-5} \) m for the Biacore T100), \( B \) is the width x length area of the flow cell (9.85 \( \times\) \( 10^{-6} \) m^2 for Biacore T100 flow cell 1), \( F_1 \) is the lower flow rate (5 \( \mu \)l/min = 8.3 \( \times\) \( 10^{-11} \) m^3/s), \( F_2 \) is the higher flow rate (100 \( \mu \)l/min = 1.7 \( \times\) \( 10^{-9} \) m^3/s), and \( \alpha \) is a conversion factor from m^3 to L (0.001 m^3/L).
When all variable values except \( m_1 \) and \( m_2 \) are known or assumed for IgG in Eq. 1, the formula for \([\text{IgG}_{\text{bulk}}] = [\text{IgG}_{\text{bulk}}] \) reduces to a much simpler equation shown in Eq. 2.

\[
[\text{IgG}_{\text{bulk}}] = \frac{\beta}{\frac{1}{m_1} - \frac{1}{m_2}}
\]  

(2)

In Eq. 2, the coefficient \( \beta = 6.5 \times 10^{-10} \) (mol * s)/(L * RU) incorporates all known variables of IgG properties and the Biacore T100 flow cell 4 in Eq. 1. For flow cells with different value of \( h \) or \( B \) in either the T100 or T200, the system software automatically incorporates these dimensional changes into the appropriate value of \( \beta \).

CFCA provides the bulk solution concentration of IgG species with affinity for the ligand in the flow cell \([\text{IgG}_{\text{bulk}}] \). The SNA flow cell therefore provides the concentration of IgG with at least one glycan exhibiting a surface accessible \( \alpha_2,6 \)-galactose-sialic acid linkage, denoted here as \([\text{IgG}]_{\text{FC,SNA}} \) [38]. The SpA flow cell provides a measurement of \( > 95\% \) of human IgG, with the CFCA concentration denoted here as \([\text{IgG}]_{\text{FC,SpA}} \) [53,54]. The O\( \alpha \)Beta flow cell provides the concentration of OA\( \beta \) + IgG, denoted here as \([\text{IgG}]_{\text{FC,O\( \alpha \)Beta}} \).

Ratios of these IgG subpopulations shown in Eq. 3ABC below provide the fraction of OA\( \beta \) + IgG in IVIG (\( F_{\text{OA\( \alpha \)Beta+IVIG}} \)), SNA-binding IgG in IVIG (\( F_{\text{SNA+IVIG}} \)), and SNA-binding IgG in mAbs 4G8 and 6E10 (\( F_{\text{SNA+mAb}} \)).

\[
F_{\text{OA\( \alpha \)Beta+IVIG}} = \frac{X_{\text{FC,O\( \alpha \)Beta}} * [\text{IgG}]_{\text{FC,O\( \alpha \)Beta}}}{X_{\text{FC,SpA}} * [\text{IgG}]_{\text{FC,SpA}}} \quad (3a)
\]

\[
F_{\text{SNA+IVIG}} = \frac{X_{\text{FC,SNA}} * [\text{IgG}]_{\text{FC,SNA}}}{X_{\text{FC,SpA}} * [\text{IgG}]_{\text{FC,SpA}}} \quad (3b)
\]

\[
F_{\text{SNA+mAb}} = \frac{X_{\text{FC,SNA}} * [\text{IgG}]_{\text{FC,SNA}}}{X_{\text{FC,O\( \alpha \)Beta}} * [\text{IgG}]_{\text{FC,O\( \alpha \)Beta}}} \quad (3c)
\]

In Eq. 3ABC, \( X_{\text{FC,SpA}} \), \( X_{\text{FC,O\( \alpha \)Beta}} \), and \( X_{\text{FC,SNA}} \) refer to associated multiplication factors that account for any dilution of the original stock IgG solutions. For brevity, the term \( F_{\text{SNA+IgG}} \) in the present article is used to refer generally to \( F_{\text{SNA+IVIG}} \) and \( F_{\text{SNA+mAb}} \) collectively or individually.

The validity of a given \([\text{IgG}] \) measurement by CFCA was determined by fulfilling two criteria. The first is that the standard error of the CFCA fit must be less than 20% of the reported \([\text{IgG}] \) concentration. The second is that the QC parameter shown in Eq. 4 exceeds 0.1 [30,31].

\[
QC = \frac{m_2}{m_1} - \frac{1}{\left( \frac{F_2}{F_1} \right)^{1/3}} - 1
\]  

(4)

QC in Eq. 4 determines the degree to which the interaction of ligand-binding IgG with the immobilized ligand is diffusion limited (i.e. mass transport limited). A partial and detectable degree of mass transport limitation is a necessary criteria for CFCA [30,31]. In theory, QC varies between 0 (no diffusion limitation) to 1 (complete diffusion limitation). While the Biacore manual suggests QC > 0.2 for CFCA, we have found that our CFCA measurements retained reliable accuracy down to QC ~ 0.1 provided the percent standard error of the fit was < 20%.

Fig. 1A and 1B show CFCA results that met the criteria using 4G8a.
Except where noted, all reported values determined from CFCA exceeded the threshold of QC > 0.1 and had a standard error less than 20% of the reported value. The QC ratio for IgG measurements of the SNA flow cell ranged between 0.2–0.3. The QC ratio for mAb binding in the OAβ flow cell ranged between 0.4–0.8. The QC ratio for IVIG binding to the SpA flow cell ranged between 0.3–0.5. The QC ratio for OAβ⁺ IgG in IVIG binding to the OAβ flow cell ranged between 0.2–0.4. These QC ratios were achieved using working dilutions of the original IgG stock solution as follows: Gammagard (10%): XFC_OAβ = 10,000, XFC_SNA = XFC_SpA = 10,000; Octagam (5%): XFC_OAβ = 50, XFC_SNA = XFC_SpA = 5,000; 6E10/4G8a mAbs (1 mg/ml): XFC_OAβ = XFC_SpA = 3,000, XFC_SNA = 1,000.

The accuracy of CFCA was also validated using 3333-fold dilutions of 6E10 and 4G8a stocks, confirmed to be 6.7 and 6.5 μM respectively by UV spectroscopy, with working test concentrations of 2.0 nM mAb. The CFCA concentration of 6E10 was determined at [IgG]FC_OAβ = 1.8 nM using both the OAβ sensor chip and the Protein A sensor chip. The CFCA concentration of 4G8 was determined at [IgG]FC_OAβ = 1.9 nM using the OAβ sensor chip (Fig. 1B) and [IgG]FC_SpA = 2.0 nM using the Protein A sensor chip. As all of these values fell within 10% of the expected value of 2.0 nM, the accuracy of the CFCA method on IgG with Protein A and OAβ sensor chips was established. Unfortunately, a reliable IgG standard for the SNA chip is not available. Given the success with Protein A and OAβ sensor chips, the accuracy of the SNA chip with CFCA was assumed to be reasonable provided the two aforementioned CFCA criteria were met.

On-Chip Analysis

As a complementary method to determine FSNA⁺ IgG, an ELISA-based “On-Chip” technique was also used to determine FSNA⁺ IgG. The On-Chip method was also used to determine FECL⁺IgG, the fraction of IgG that bound ECL, a lectin specific to terminal galactose residues with an α1,4 linkage to a preceding N-acetylglucosamine [55]. The On-Chip method involves an initial binding step of IgG followed with a second binding step with excess SNA (3 μM) or excess ECL (33 μM).

A representative example of FSNA⁺IgG measurement of 4G8a in the OAβ flow cell is shown in Fig. 2. All On-Chip FSNA⁺IgG measurements for 6E10 and 4G8 were performed using the OAβ flow cell. For IVIG, the SpA flow cell was used to determine FSNA⁺ IgG for total IVIG and the OAβ flow cell was used to determine FSNA⁺ IgG of the OAβ⁺ IgG subgroup.

Regardless of whether the immobilized ligand in the flow cell was SpA or OAβ or whether the initial IgG measured was IVIG or mAb, the fraction of SNA or ECL Lectin-binding IgG (FL⁺IgG) was determined using Eq. 5.

\[
FL⁺IgG = \frac{M \cdot (RU_{L⁺IgG} - RU_{L⁻IgG})}{RU_{IgG}}
\]

In Eq. 5, RU_{IgG} is the SPR response units of the first binding step involving IgG (~1300 RU in Fig. 2). RU_{L⁺IgG} is the SPR response units produced in the second binding of lectin with IgG bound to the sensor (~270 RU in Fig. 2). RU_{L⁻IgG} is a background control on the flow cell without IgG bound (~130 RU in Fig. 2) and is subtracted from RU_{L⁺IgG} to determine the true value of SNA binding (~140 RU). M is the mass ratio of 150 kD IgG to lectin L (1.07 for 140 kD SNA, 2.78 for 57 kD ECL) [38,55]. FSNA⁺IgG denotes the value of FL⁺IgG for SNA lectin and FECL⁺IgG denotes the value of FL⁺IgG for ECL lectin.

The On-Chip method was also used to determine the extent to which EndoS enzyme reduces SNA-binding by selective cleavage of the Fc glycan. The susceptibility of FSNA⁺IgG to
EndoS treatment was represented by the variable \( F_{\text{EndoS}} \) in Eq. 6.

\[
F_{\text{EndoS}} = \frac{F_{\text{SNA+IgG}(+\text{EndoS})}}{F_{\text{SNA+IgG}(-\text{EndoS})}} \tag{6}
\]

In Eq. 6, \( F_{\text{SNA+IgG}(+\text{EndoS})} \) refers to \( F_{\text{SNA+IgG}} \) of an IgG sample pretreated with EndoS enzyme and \( F_{\text{SNA+IgG}(-\text{EndoS})} \) refers to \( F_{\text{SNA+IgG}} \) of an IgG sample with “mock” EndoS enzyme treatment.

The criteria of On-Chip analysis is that a sufficiently high initial IgG binding is achieved in Step 1 to enable a reliable determination of SNA binding in Step 2. We have determined this minimum threshold to be approximately 50 RU of IgG bound. However, in most cases, the value of \( R_{\text{U}_{\text{IgG}}} \) ranged between 500–1500 RU depending on the IgG product and preparation prior to SPR analysis. High values of IgG binding were achieved using IgG solution concentrations in On-Chip analysis as follows: (1) 100 nM (15 µg/ml) 6E10 or 4G8 mAb, (2) 2.7 µM (400 µg/ml) IVIG using the SpA flow cell, and (3) 27 µM (4000 µg/ml) IVIG using the OAβ flow cell.
SDS-PAGE and Lectin Blots

SDS-PAGE and Lectin Blots used 4–20% Tris-HCl Ready Gels (Bio-Rad). Antibody samples were mixed 1:1 with Laemmli Sample Buffer (Bio-Rad) with a loading concentration of 1% SDS, heated to 95°C for 2 minutes and electrophoresis performed with Tris-Glycine-SDS (0.1% SDS) running buffer on a MiniProtean II (BioRad). Kaleidescope prestained standards (BioRad 161–0324) were run in the end lanes. Standard SDS-PAGE gels were imaged used Coomassie Blue staining, followed by fixing and destain steps. For Lectin Blotting, proteins were transferred to Westran S PVDF membranes (Whatman) using an iBlot system (Invitrogen). The membrane was blocked using Carbohydrate-free blocking buffer (Vector Labs) followed by overnight incubation at 4°C with biotinylated SNA (100 μg/ml). After washing, the membrane was incubated for 1 hour at room temperature with Qdot 625 streptavidin conjugate (Invitrogen, A10196, 1:1000 dilution of 1 μM stock). Bands were visualized and imaged with a Gel Logic 100 Digital Imaging System (Kodak) using a Dark Reader Transilluminator (Clare Chemical).

Statistics

All quantitative data measurements were performed either in duplicate (n = 2) or triplicate (n = 3) as indicated in the Figure legends. All error bars shown in the Figures are the standard deviation of a given set of replicated measurements. While many potential comparisons of data sets in the present work were possible, the following data set comparisons were considered most relevant: (A) The same IgG with different enzymatic treatment conditions and (B) Different IgG species with the same enzymatic treatment condition. Prior to more intensive statistical analysis, single variable ANOVA was used on all data sets corresponding to comparison A or B to avoid Type I errors and confirm statistically significant differences. If the ANOVA p-value was less than 0.1, a two-tailed student’s t-test was performed on each data pair in all comparisons A and B to determine those with the greatest statistical significance and lowest p-values. The lowest p-values determined through this analysis are shown in Figures by letter and asterisk superscripts. All statistical analysis was performed using the statistical functions and ANOVA toolpack of Microsoft Excel 2010.

Results

CFCA and the On-Chip method are complementary approaches to quantify IgG subpopulations

Representative CFCA experiments using mAb 4G8 Lot A (4G8a) as the IgG species are shown in the flow cell with immobilized SNA lectin ligand (Fig. 1A) and with immobilized OAAβ ligand (Fig. 1B). SPR slopes are shown under low flow at 5 μl/min and under high flow at 100 μl/min. Using Eq. 1 and Eq. 2 in Methods and Materials, these slopes are used to determine the bulk concentration of ligand-binding IgG in the solution passing through the flow cell [30]. In both Fig. 1A and1B, a mass transport limitation is qualitatively evident by the difference in the low and high slopes [31]. The use of CFCA is validated quantitatively by QC parameters > 0.1 (Eq. 4) and standard error SE < 20%.

Fig. 1A shows immobilized SNA binding from a 833-fold dilution of 4G8a. Because only a fraction of antibodies exhibit surface sialic acid, the SNA-binding concentration is always less than the total IgG concentration [16,28,29,39–41]. Despite attempts to increase immobilized SNA the QC parameters for IgG binding in the SNA-flow cell were generally modest and ranged between 0.2–0.3.
Data in Fig. 1B shows OAβ binding in a 3333-fold dilution of 4G8a. For anti-Ab mAbs such as 4G8 and 6E10, the data in Fig. 1A will determine the total concentration of these mAbs assuming they are 100% active. If the solution measured in the OAβ-flow cell is serum IgG or IVIG, the determined concentration of OAβ+ IgG will be less than that of total IgG. The SPR association slopes in Fig. 1B are highly linear and well separated, resulting in the high QC ratio of 0.63. In general, this was observed for all OAβ+ IgG binding from mAbs and IVIG, consistently yielding QC parameters between 0.5–0.8.

CFCA analysis shown in Fig. 1A and 1B was used for IVIG and for anti-Aβ mAbs 6E10 and 4G8. CFCA was also performed using a flow cell with immobilized Protein A (SpA) to determine the post-preparation concentration of human IgG in the IVIG samples [54]. To compare Octagam, Gammagard, and OAβ+ mAb references, three fractional values were determined using Eq. 3A-3C (Methods and Materials). The fraction of OAβ+ IgG in IVIG (\(F_{OAβ+IVIG}\)) was determined using Eq. 3A. The fraction of SNA+ IgG in IVIG (\(F_{SNA+IVIG}\)) was determined using Eq. 3B. The fraction of SNA+ IgG in mAbs (\(F_{SNA+mAb}\)) was determined using Eq. 3C. For clarity, the term \(F_{SNA+IgG}\) indicates either \(F_{SNA+IVIG}\) and/or \(F_{SNA+mAb}\).

Values of \(F_{SNA+IgG}\) from CFCA were also confirmed using the On-Chip method shown in Fig. 2. For consistency with Fig. 1, 4G8a is also used in Fig. 2. The On-Chip method initially captures IgG using either immobilized SpA or OAβ in Step 1. The SPR signal produces a response \(R_{U_{IgG}}\). After a brief equilibration period, excess SNA lectin (3 \(\mu\)M) is introduced in Step 2, producing a second binding response \(R_{U_{L+IgG}}\) resulting from SNA binding to the IgG. To account for SNA binding to the sensor surface, a control without IgG is performed to determine the background response \(R_{U_{L-IgG}}\). Once the sample and background control are measured, \(F_{L+IgG}\) is determined using Eq. 5 (Methods and Materials).

If SNA lectin was used, \(F_{L+IgG}\) is specified as \(F_{SNA+IgG}\) (Fig. 2). A similar On-Chip method to that shown in Fig. 2 was performed using 33 \(\mu\)M ECL lectin instead of 3 \(\mu\)M SNA. ECL ligand is used to quantify the fraction of IgG with surface-accessible galactose groups at glycan termini. If ECL lectin was used, \(F_{L+IgG}\) is specified as \(F_{ECL+IgG}\).

Octagam contains a higher fraction of anti-OAβ IgG than Gammagard

CFCA was used to measure and compare \(F_{OAβ+IVIG}\) in Octagam and Gammagard (Fig. 3). The result was that \(F_{OAβ+IVIG}\) for Octagam (0.00025) is approximately twice that of Gammagard (0.00012). The concentration of Octagam OAx+ IgG was reported at approximately 1.5 times that of Gammagard in a previous ELISA study [19]. As a possible explanation for the discrepancy in magnitude, Aβ peptides in the previous study had been disaggregated prior to immobilization. Nonetheless, both studies find that Octagam has a higher fraction of Ax-binding IgG than Gammagard.

The \(F_{OAβ+IVIG}\) determined here by CFCA for 10% Gammagard indicates an OAβ IgG concentration in this product that is approximately 2-fold higher (70 nM) than that measured in a previous ELISA study (~35 nM) [24]. While this difference is not excessive, the exact explanation is not known. One possible explanation is simply that slight differences in oligomer preparation and analytical methodology allow different or weaker-binding OAβ IgG binding in SPR versus ELISA. Another possible factor is that the nonspecific background binding from Gammagard was very high by ELISA, at ~50% of total OAβ+ IgG binding [24]. By contrast, in SPR measurements of IVIG, the background signal rise in the reference cell never exceeded 10% of that in the OAβ flow cell. Given the lack of nonspecific binding, CFCA may be providing a more accurate value of \(F_{OAβ+IVIG}\).
Octagam and Gammagard have similar fractions of SNA-binding IgG

Fig. 4 shows a comparison of the fraction of SNA-binding and ECL-binding IgG in IVIG and of mAbs 6E10 and 4G8. In addition, the values of $F_{\text{SNA}+\text{IgG}}$ and $F_{\text{ECL}+\text{IgG}}$ are determined in untreated IgG products after treatment with 2,6 sialyltransferase (2,6ST) and after treatment with neuraminidase (NEU). Fig. 4A and 4B show values of $F_{\text{SNA}+\text{IgG}}$ determined by CFCA and the On-Chip method respectively. Fig. 4C confirms these findings with values of $F_{\text{ECL}+\text{IgG}}$ determined by the On-Chip method. Due to a high variability noted for $F_{\text{SNA}+\text{IgG}}$ between lots of mAb 4G8, the individual 4G8 lot values are shown as 4G8a and 4G8b.

Both Fig. 4A and 4B show a similar profile of $F_{\text{SNA}+\text{IgG}}$ values. Untreated 4G8b is marginally higher than untreated 4G8a, Octagam, and Gammagard, with all four untreated IgGs being higher than untreated 6E10. Treatment with 2,6ST produced no increase in the IgG except a statistically marginal increase in 4G8a ($0.10 < p < 0.13$) and 4G8b ($0.08 < p < 0.10$). By contrast, NEU-treatment produced a statistically significant reduction in all IgG to $F_{\text{SNA}+\text{IgG}} \sim 0$. The exception is On-Chip 6E10 in Fig. 4B, which showed marginal statistical significance ($0.10 < p < 0.13$) between untreated and NEU-treatment conditions. This is due largely to similar mean values of 6E10 $F_{\text{SNA}+\text{IgG}}$ that are close to zero and is not the result of high error in measurements of this IgG species.

Fig. 4C is consistent with Fig. 4A and 4B because $F_{\text{ECL}+\text{IgG}}$ is expected to be inversely correlated with $F_{\text{SNA}+\text{IgG}}$. Sialylated glycan termini do not bind ECL and removal of sialic acid will yield a terminal galactose with affinity for ECL. A notable exception is that a higher $F_{\text{ECL}+\text{IgG}}$ is...
Fig 4. Surface sialic acid is similar between IVIG products and but varies in anti-Aβ monoclonal antibodies. Measurement of the SNA-binding fraction ($F_{SNA+IgG}$) and ECL-binding fraction ($F_{ECL+IgG}$) in Octagam IVIG (OCT), Gammagard IVIG (GG), mAb 6E10, and mAb 4G8 using CFCA (A) and the On-Chip method (B,C). Two different lots of mAb 4G8 are shown as 4G8a and 4G8b. Each IgG was enzymatically untreated (black bars), 2,6 sialyltransferase treated (2,6ST, light grey bars), and neuraminidase treated (NEU, dark grey bars). Error bars indicate standard deviations (n = 2). CFCA measurements of
found for untreated and 2,6ST-treated 6E10 versus NEU-treated 6E10. Although this difference is of weak statistical significance (0.13 < p < 0.19), it is clearly not the inverse of the 6E10 F_{SNA+IgG} values shown in Fig. 4B. Excepting this 6E10 case, the F_{ECL+IgG} of all other NEU-treated IgG were higher than their corresponding untreated and 2,6ST-treated forms. This NEU-treated increase in F_{ECL+IgG} was statistically significant (p < 0.08) for Octagam, 4G8a, and 4G8b and marginally significant for Gammagard (0.11 < p < 0.13). In addition, a small but statistically significant increase in F_{ECL+IgG} was found when untreated Octagam was treated with 2,6ST. Despite these minor exceptions, the magnitude of F_{ECL+IgG} of a given IgG sample in Fig. 4C is generally inversely correlated with the values of F_{SNA+IgG} in Fig. 4A and 4B.

Despite similar trends in Fig. 4A and 4B, a notable difference was that CFCA consistently predicted a higher value of F_{SNA+IgG} that the On-Chip method. With no biochemical standard of F_{SNA+IgG} available, it was unclear whether F_{SNA+IgG} is more accurately determined from CFCA or the On-Chip method. Fractional yields of IVIG from SNA affinity chromatography have been reported between 0.10–0.13 [29,39]. These literature values fall closer to the On-Chip measurement of F_{SNA+IgG} (0.08–0.10) than those by CFCA (~0.30). However, SPR sensor binding measurements and column purification yields involve different factors. This issue required empirical investigation to resolve.

A logical supposition is that CFCA is more accurate because IgG bound in the On-Chip method would not expose all available SNA binding sites. To test this hypothesis, a control experiment was needed in which an analyte with known binding stoichiometry to IgG could be substituted for SNA in Step 2. This control experiment was possible if 4G8 was bound to immobilized OAβ in Step 1 and analyte SpA used to bind this IgG2 mouse subtype in Step 2. Previous studies have shown empirically that 1:1 Fc:SpA binding predominates at excess SpA [53,56]. Given the SpA mass of 42 kD and IgG mass of 150 kD, a Step2/Step1 signal ratio of 0.28 is expected if all binding sites available in solution remain available after 4G8 is immobilized.

Fig. 5A shows a representative SPR sensogram of this control measurement, with a Step 2/Step 1 RU ratio of 0.178 +/- 0.005. This value is less than the expected value of 0.28 and corresponds to an On-Chip molar ratio of SpA:4G8 of 0.636. This result supports the premise that IgG binding to the sensor ligand results in an increase in steric hindrance for subsequently introduced IgG-binding analytes. Having established that SpA binding sites were 36.4% less accessible after IgG binding to the sensor chip, it was logical to ask if this same level of steric hindrance was also found with SNA binding sites.

To address this question, the On-Chip values of F_{SNA+IgG} in Fig. 4B were multiplied by the reciprocal of the SpA:4G8 molar ratio, 1/0.636 = 1.57, and the results are shown in Fig. 5B. In Fig. 5B, the correlation of these SpA-adjusted On-Chip values versus CFCA (grey data points) is shown along with raw On-Chip values versus CFCA (black data points). The raw correlation between On-Chip values and CFCA in Fig. 5B did not differ significantly between mAb data (black open circles, 0.38) and IVIG data (black filled circles, 0.34). Steric hindrance at SNA-binding sites in the On-Chip method was deemed to be similar regardless of whether mAb was...
Fig 5. Steric hindrance at IgG binding sites increases after IgG binds ligands on the sensor surface.
(A) Representative SPR On-Chip experiment on a 60-fold dilution of 4G8 captured in a flow cell with immobilized OAβ. In Step 1, IgG (4G8) is bound for 120 s and the association binding signal RU(4G8) measured. In Step 2, 1 μM SpA is bound for 180 s to the flow cell containing 4G8 and this second association...
bound to the O\(\beta\) chip or IVIG was bound to the Protein A chip. Using mAb and IVIG data together, Fig. 5B shows that the total On-Chip versus CFCA slope increases from 0.37 (black points/line) to 0.58 (grey points/line) after the SpA-adjustment is applied. The empirical 1.57 SpA adjustment factor corrects for some, but not all, of the 2.7-fold discrepancy in FSNA+IgG between CFCA and the non-adjusted On-Chip data. Because the adjusted slope remains less than 1.0 after SpA-adjustment, the steric hindrance of SpA appears to be less than that of SNA. It is concluded that the degree of steric hindrance for surface-bound IgG cannot be assumed for different analytes with different molecular configurations and binding properties. For example, SpA is smaller than SNA and likely encounters less steric repulsion when binding. In addition, an analyte with polyvalent capability would more effectively hinder its fellow analytes from binding IgG binding by occupying multiple sites. While a full investigation of such factors is outside the scope of the present study, the relevant finding in Fig. 5 is that analyte binding to surface-bound IgG is sterically hindered. CFCA is therefore presumed to be more accurate for FSNA+IgG determination.

While the On-Chip method may not be accurate as CFCA for FSNA+IgG determination, it did demonstrate high precision. This high precision is shown in Fig. 5B by the high correlation coefficient of the linear fit between CFCA and the On-Chip data (\(r^2 = 0.94\)). Also, the overall slope was similar between IVIG data (FSNA+IVIG, filled symbols) and mAb data (FSNA+mAb, open symbols). Thus, the On-Chip method can be used to precisely compare relative changes in FSNA+IgG between different IgG preparations and with different sensor chips. Because CFCA was used as a benchmark in the present study, an empirical correction factor of 2.7 for all On-Chip values of FSNA+IgG can be used to adjust the On-Chip values to be consistent with CFCA. This correction factor of 2.7 only applies to SNA and not to other analytes used in Step 2 of the On-Chip analysis.

IVIG surface-accessible sialic acid is predominantly located on the Fab domain

To determine if Octagam and Gammagard differ in sialic acid location, SDS-PAGE and lectin blots were used initially (Fig. 6). SDS-PAGE in Fig. 6A shows that Octagam and Gammagard are comprised of light (IgGL) and heavy (IgGH) chain bands near the expected masses of 25 and 50 kD respectively. However, a clear picture of IgGL and IgGH states in IVIG is complicated by diffuse primary IgGL and IgGH bands and also many higher molecular weight bands. The bands of mAbs 4G8 and 6E10 were much simpler than those of IVIG. While simpler than IVIG, 4G8 does exhibit two well-resolved bands for both IgGL and IgGH. By contrast, 6E10 shows only a single discernible band for both IgGL and IgGH. One explanation for additional IgGL and IgGH bands in Fig. 6A is the presence of glycans bound in the respective V\(_L\) and V\(_H\) regions of these chains [29,39].
SNA lectin blotting was used to assess the degree of sialylation present in these IgG bands (Fig. 6B). When imaging high protein concentrations using WesternDot on a Dark Reader, both non-fluorescent proteins are observed (light bands) along with the blot-specific bands (dark bands). For IVIG bands in Fig. 6B, one notes a weak intensity of blotting on the upper portion of both the heavy and light chain bands (rectangles). SNA blotting of 4G8 is most pronounced on the heavier of the two IgG bands (circle), indicating that 4G8 sialylation occurs primarily on Fab glycans. SNA blotting is found only on the IgG band of 6E10 (square).

To further assess whether the slower migrating bands are the result of additional N-linked glycans to IgG chains, mAb samples (Fig. 6C) and IVIG samples (Fig. 6D) were run untreated and after treatment with PNGase F. In Fig. 6C, 6E10 shows no discernable difference in bands excepting the added PNGase F band indicated by "P" at 36 kD. By contrast, the heavier IgG bands...
band of 4G8 (highlighted by arrow), but not the heavier IgGII band, is removed after PNGase F treatment. PNGase F treatment of IVIG is complicated by the presence of multiple bands (Fig. 6D). Despite this complexity, two band regions of untreated IVIG are noted with reduced intensity after PNGase F treatment. Similar to 4G8, one such band migrates slightly slower than IgG1 (lower arrow). In addition, an upper band that migrates slightly faster than IgGH is not evident in the PNGase F lanes (upper arrow). Taken together, the primary sialylation sites appear to be limited to the conserved Fc glycan (6E10, IVIG) or to a lone additional glycan bound to the IgG1 domain (4G8, IVIG). Although 4G8 and IVIG bands are observed that migrate slower than IgGIII, their insensitivity to PNGase F treatment indicates they do not possess N-linked glycans.

In Fig. 6, sialylation on 6E10 appears entirely on the Fc domain while sialylation on 4G8 appears entirely on the Fab domain. Thus, SNA binding to these mAbs is expected to occur with sialic acid occupying one of these two domains exclusively. For IVIG, the relative fraction of total sialic acid on Fc and Fab domains is more difficult to quantify in Fig. 6. In addition, it has been reported that Fab sialic acid preferentially binds SNA over Fc sialic acid. To resolve this ambiguity, the primary domain of surface sialic acid in Octagam and Gammagard was determined through enzymatic treatment with Fc-specific endoglycosidase EndoS.

Given the quantitative limitations of the Lectin Blots, SPR was used to quantitatively determine the fraction of accessible sialic acid associated with the conserved Fc glycan. For this experiment, IgG was treated with and without EndoS enzyme which selectively cleaves Fc glycans. The remaining fraction of SNA-binding attributed to non-Fc glycans (F_{EndoS}) was then determined using Eq. 6 [57]. A lower value of F_{EndoS} corresponds to a greater fraction of surface sialic acid associated with the Fc glycan. A high value of F_{EndoS} indicates that most surface sialic acid is associated with other glycans in the Fab domain.

Fig. 7 shows results for 6E10 and 4G8 that are consistent with Fig. 6. Briefly, F_{EndoS} is close to zero for 6E10 and close to 1.0 for 4G8a and 4G8b. For Octagam and Gammagard, F_{EndoS}...
was shown to be similar to 4G8 at approximately 0.9. Consistent with previous reports, surface sialic acid is primarily associated with Fab glycans in most IVIG antibodies.

**OAβ⁺ IgG in IVIG contains surface sialic acid lacking the α2,6 linkage**

Significant levels of OAβ⁺ IgG (Fig. 3) and surface sialic acid (Fig. 4) were detected in Octagam and Gammagard IVIG. Because these two individual properties are potentially relevant to AD treatment, IgG subgroups with both of these properties in IVIG are of particular interest. To date, this combined measurement has not been performed in IVIG. CFCA is accurate but only can only measure one of these two properties at a time. Having been validated in the present study, the On-Chip method was appropriate for quantifying the IgG sub-subpopulation in IVIG with both OAβ⁺ and SNA⁺ or ECL⁺ binding affinities. Analogous to the 4G8 experiment shown in Fig. 2, OAβ⁺ IgG from IVIG was captured in Step 1 and excess SNA or ECL lectin binding was performed on the captured OAβ⁺ IgG in Step 2.

Fig. 8A and 8B show the values of FSNA+IgG and FECL+IgG respectively of OAβ⁺ IgG in untreated, 2,6ST-treated, and NEU-treated IVIG. In addition, each enzymatic treatment of IVIG was performed with and without EndoS post-treatment to determine the extent of Fc glycan contribution to FSNA+IgG and FECL+IgG. Fig. 8A shows that only 2,6ST-treated OAβ⁺ IgG shows a higher value of FSNA+IgG ~ 0.2 versus the other treatment conditions, which exhibited statistically insignificant values. While the statistical significance of this measurement is marginal because of a low OAβ⁺ IgG binding response on the chip, a value of 2,6ST-treated FSNA+IgG of ~ 0.2 was observed for both Octagam (0.10 < p < 0.20) and Gammagard (0.05 < p < 0.08). The lower value of FSNA+IgG for 2,6ST/EndoS-treated OAβ⁺ IgG indicates that the substrate for this enzymatic sialylation is the Fc glycan.

Compared with Fig. 8A, Fig. 8B shows surprising results from FECL+IgG measurements. Untreated IVIG did not show a significant FECL+IgG. However, 2,6ST treatment produced an unexpected high value of FECL+IgG ~ 0.2. Although statistically marginal, this increased value was found for both Octagam (p = 0.17) and Gammagard (0.05 < p < 0.09) and was not observed after 2,6ST/EndoS treatment for both IVIG. A second unexpected result in Fig. 8B was the finding that both NEU-treatment and NEU/EndoS-treatment produced a high value of FECL+IgG ~ 0.35 for OAβ⁺ IgG. This was observed in both Octagam and Gammagard. Thus, endogenous human OAβ⁺ IgG exhibits surface sialic acid that does not bind SNA and is likely of a different biochemical linkage than that of 6E10, 4G8, and most other human IgG antibodies.

**Discussion**

The results demonstrate that the properties of Octagam and Gammagard studied here are quite similar. The largest difference was FOAβ⁺IVIG in Octagam being approximately twice that of Gammagard, though it was of marginal statistical significance (p = 0.10 in Fig. 3). This result is consistent with a previous ELISA study and is a second example showing Octagam with more Aβ-specific IgG than Gammagard[19]. Both results shed light on the clinical hypothesis that AD patients would benefit from increased levels of anti-Aβ IgG [10,18].

Assuming a 400 mg/kg IVIG dose, 100 kg patient, 7 liters of blood, 100 ml of cerebrospinal fluid (CSF) and 0.1% total IgG peak brain penetration, picomolar OAβ⁺ IgG concentrations in the CSF are expected in the peak timeframe after IVIG infusion [58]. This estimate is supported by a small study of patient CSF after Octagam treatment which indicated an increase of anti-Aβ IgG CSF concentration from 10 to 70 pM [10]. Because estimates of OAβ⁺ IgG binding thermodynamics estimate a nanomolar affinity, variation of picomolar CSF OAβ⁺ IgG concentrations could possibly result in different clinical outcomes [18,27,36]. Given the elevated FOAβ⁺IVIG in Octagam versus Gammagard, this clinical hypothesis predicts that Octagam would show more
Fig 8. OAβ+ IgG in IVIG exhibits a high fraction of Fab surface sialic acid lacking α2,6 linkages. On-Chip SPR measurement of (A) the SNA-binding fraction (F_{SNA+IgG}) and (B) the ECL-binding fraction (F_{ECL+IgG}) of OAβ+ IgG in Octagam IVIG (OCT) and Gammagard IVIG (GG). In each set of six, bars 1,2 indicate results without 2,6ST or NEU pre-treatment, bars 3,4 indicate results with 2,6ST pre-treatment, and bars 5,6 indicate NEU pre-treatment. Back bars indicate no post-treatment and white bars indicate EndoS post treatment. Error bars represent standard deviations (n = 2). The statistical significance of the
positive clinical outcomes than Gammagard. Recent clinical trials reported small and patient-selective benefits from Gammagard and no benefit from Octagam treatment [2,3]. Thus, the clinical relevance of natural anti-Aβ IgG alone remains unclear.

OAβ+ IgG and surface sialic acid did not correlate with the reported clinical outcomes of Octagam and Gammagard. However, unique glycosylation properties of the OAβ+ IgG subgroup in IVIG were identified. Modulation of these unique glycosylation features might lead to better IVIG treatments for AD. The primary finding here was that approximately one third of OAβ+ IgG in IVIG exhibited terminally-sialylated Fab glycans completely lacking the standard α2,6 linkage to galactose (Fig. 8).

Examination of Fig. 8A shows F_{SNA+IgG} ~ 0 for both untreated and NEU-treated OAβ+ IgG. Surface sialic acid with the α2,6 glycan linkage is therefore not present in endogenous OAβ+ IgG. In Fig. 8B, untreated OAβ+ IgG also showed a F_{ECL+IgG} ~ 0, indicating a lack of any surface glycans with terminal galactose in endogenous OAβ+ IgG. However, the high value of F_{ECL+IgG} ~ 0.35 in NEU-treated OAβ+ IgG unveiled a significant number of galactose groups after an apparent cleavage of many SNA-insensitive sialic acids. To account for the lack of SNA binding in untreated samples, the naturally occurring sialic acid in endogenous OAβ+ IgG must be bonded to galactose through linkages other than the α2–6 orientation. The similar F_{ECL+IgG} values between NEU-treated and NEU/EndoS-treated OAβ+ IgG further indicate that the non-α2,6 sialic acid groups reside in the Fab domain.

Another notable finding in the OAβ+ IgG glycosylation results in Fig. 8A and 8B is that 2,6ST treatment yielded OAβ+ IgG with increased binding affinity to both SNA and ECL. Because 2,6ST/EndoS treatment eliminated both SNA and ECL binding, it is concluded that both lectins are binding at the Fc glycan of 2,6ST-treated OAβ+ IgG. The ECL sensitivity to EndoS of OAβ+ IgG differs from that of 4G8 and IVIG but not 6E10. Like OAβ+ IgG, 6E10 also showed a higher F_{ECL+IgG} after 2,6ST treatment in Fig. 4C and highlights two possibilities. First, 2,6ST-treatment may not completely sialylate the sterically hindered Fc glycans. Second, this partial Fc sialylation may alter the IgG structure such that residual Fc galactose groups are more exposed. The different magnitudes of F_{ECL+IgG} values between NEU-treated and NEU/EndoS-treated OAβ+ IgG further indicate that the non-α2,6 sialic acid groups reside in the Fab domain.

A previous LC/MS study reported N297 Fc glycan sialylation to be similar between IVIG and its anti-Aβ IgG subgroup [41]. However, the present study and others shows that surface sialic acid in the Fab domain is primarily responsible for SNA binding in untreated IVIG, with minimal contribution from sialic acid on the Fc glycan [29,39,40]. Because the present study does not rule out the presence of buried sialic acid at the N297 glycan of OAβ IgG, the results here are not in conflict with this prior LC/MS study [41].

The absence of α2,6-linked surface sialic acid in natural OAβ+ IgG reported here is consistent the previous study with a mouse model of nephrotoxic nephritis [28]. In this study, antigen-specific IgG showed significantly lower levels of SNA binding after a secondary exposure to the antigen [28]. While a valuable study, the authors suggested that the loss of SNA binding was due to the loss of sialic acid and did not investigate if sialic acid was actually present on the IgG in non-α2,6 linkages. The present results demonstrate that non-α2,6 linked sialic acid can also occur in antigenic IgG.
It remains unclear whether an anti-OA\(\beta\) immune response helps AD patients or if it instead leads to unintentional exacerbation of AD pathology [17]. The present study provides perspective on this question because it demonstrates that OA\(\beta\)\(^+\) IgG in Octagam and Gammagard clinical trials was delivered to AD patients with sialic acid in an atypical biochemical linkage to galactose (Fig. 8). It is not known if current anti-A\(\beta\) antibody drugs for AD also present atypical sialic acid linkages on their surface [4,5]. A mass spectroscopy analysis of N-glycans cleaved from multiple commercial therapeutic antibodies indicated that the sialic acid level in these antibody drugs is typically very low [59]. As an exception, glycans of HIV-neutralizing antibody 4E10 are found to be highly sialylated and can preferentially exhibit \(\alpha_2,3\) or \(\alpha_2,6\) linkages depending on expression conditions [59]. Extracellular expression of \(\alpha_2,3\) and \(\alpha_2,6\) sialic acid levels on membrane glycoproteins delineates species susceptibility to viral infection [60]. However, the biological impact of different sialic acid linkage isomers is less clear when part of proteins such as IgG [60].

One new route of investigation for AD treatment would be to investigate natural human anti-A\(\beta\) oligomer antibodies with glycans presenting the typical \(\alpha_2,6\)-linked surface sialic acid moiety. The \(\alpha_2,6\)-linked sialic acid can be produced using initial NEU treatment, followed by 2,6ST treatment and/or enrichment with SNA affinity chromatography [29,39,40,61]. This newer formulation of \(\alpha_2,6\)-sialylated OA\(\beta\)\(^+\) IgG may more effectively reduce neuroinflammation in addition to reducing OA\(\beta\) levels in the brain [16,29,61]. Evidence also suggests that surface sialic acid properties modulate protein permeability through the blood-brain barrier, a property that could enhance IgG treatment of AD [62,63]. Given the potential of antibody therapy for AD, continued efforts to modulate bioactivity of existing therapeutic IgG through changes in surface glycosylation are warranted.

Another relevant finding is that endogenous IVIG surface sialic acid is primarily located on Fab glycans. A debate exists in the literature regarding the primary location of surface sialic acid in IVIG. This question is relevant to IVIG clinical applications because enrichment of sialylated IgG after affinity chromatography with SNA lectin is associated with anti-inflammatory outcomes in select autoimmune disease models [28,29,61]. A number of studies have inferred the location of this “functional” sialic acid in IVIG by measuring the change in Fab and Fc sialylated glycan populations before and after SNA affinity chromatography [29,39,40]. The work here also addressed the question of surface sialic acid location in IVIG but with different experimental tools, i.e. SPR and enzymatic treatments. All studies in the present work reach the same conclusion—that IVIG surface sialic acid with SNA affinity is predominantly associated with N-linked Fab glycans. Additionally, Fab surface sialic acid also predominates on the OA\(\beta\)\(^+\) IgG subgroup but with a linkage orientation that prevents SNA binding.

SNA binding of IVIG and 4G8 antibodies is primarily mediated by sialylated glycans in the Fab domains. However, the present results with 6E10 (Fig. 4A,4B) and 2,6ST-treated OA\(\beta\)\(^+\) IgG (Fig. 8A) do show that sialylated Fc glycans can also facilitate SNA binding. Binding between sialylated Fc glycans and SNA on affinity columns has been noted previously for IgG preparations where sialylated Fab glycans were not present [29,39]. Thus, sialylated Fc glycans are not completely inaccessible on the IgG surface to lectin binding.

Previous studies also indicate that Fc sialic acids are more sterically hindered and do not bind SNA as well as Fab glycan sialic acids [39]. This idea was supported by lower sialic acid enrichment efficiency of isolated Fc domains relative to Fab fragments using SNA affinity chromatography [29]. The low F_{SNA+IgG}~0.04 of 2,6ST-treated 6E10 in Fig. 4A and 4B is consistent with these previous studies. However, the relatively high F_{SNA+IgG}~0.20 of 2,6ST-treated OA\(\beta\)\(^+\) IgG in Fig. 8A results from Fc sialylation and exceeds that of Fab-sialylated total IVIG (F_{SNA+IgG}~0.10) in Fig. 4B. Thus, factors other than Fc/Fab domain location may influence the surface-accessibility of terminal sialic acids on IgG glycans.
The biological activity of Fc and Fab glycan sialic acid moieties, and their different possible biochemical orientations, is largely unknown. Enrichment of IgG from IVIG with affinity for SNA has been shown to reduce inflammation in some disease models [28,29]. The exact mechanism of how this occurs is not known although altered antigen binding may be involved [29]. While Fc sialic acid is minimally enriched by SNA affinity chromatography of IVIG, it is also possible that Fc sialylation may alter IgG biological activity. One proposed hypothesis is that sialylation of the Fc glycan changes the Fc structure through internal interactions which alters affinities between different binding partners [64]. Testing this hypothesis is beyond the scope of the present study but this is an intriguing subject for future work.

From a methodological perspective, the present work demonstrates the use of two complementary SPR methods for the study of subgroups in complex polyclonal IgG preparations. CFCA is the best method to obtain accurate concentration measurements of IgG with a single binding property. The On-Chip method proved to be useful in measuring an IgG sub-subfraction within polyclonal IgG preparations capable of binding two separate proteins. Using these two methods together is important because future antibody research for AD will likely develop antibodies that bind multiple targets [65]. Efforts are currently underway to develop bifunctional antibodies that both bind the blood-brain barrier and also target Aβ peptides [66]. In line with these efforts, the two SPR methods used here provide useful tools to accurately characterize the next generation of antibody therapeutics for AD.

Supporting Information

S1 Table. Tables of data and errors shown in Figs. 3, 4A, 4B, 4C, 5B, 7, 8A, and 8B. IgG comprising x-axis categories in Figs. 3, 4A, 4B, 4C, and 7 are shown in the far left column. The IgG x-axis categories in Fig. 8A are shown under the column titled “SNA” and the IgG x-axis categories in Fig. 8B are shown under the column titled “ECL”. Means and standard deviations shown on the y-axis of Figs. 3, 4A, 4B, 4C, 7, 8A, and 8B are listed under column titles “Mean” and “SD” respectively. For Fig. 4A and 4B data, y-axis means and standard deviations of untreated, 2,6-sialyltransferase-treated, neuraminidase-treated IgG are designated with the column titles “Untreated”, “2,6ST”, and “NEU” respectively. For Fig. 5B, the raw x-axis are shown under the column “CFCA”, the unadjusted y-axis On-Chip raw data are shown under the column “On-Chip (raw)”, and the adjusted y-axis On-Chip raw data are shown under the column “On-Chip (adjusted)”. For Fig. 5B data, the x-y pairs of all IgG data, IVIG data alone, and monoclonal antibody data alone are designated with the column titles “All data”, “IVIG data”, and “mAb data” respectively.

(PDF)

Author Contributions

Conceived and designed the experiments: HK JMF. Performed the experiments: HK ACC HS JMF. Analyzed the data: HK JMF. Contributed reagents/materials/analysis tools: HK JMF. Wrote the paper: HK JMF.

References

1. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Annu Rev Public Health 2002; 23: 213–231. PMID: 11910061
2. Kyhos B, Spak D (2013). “GAP 18-Month Study Results, http://www.baxter.com/gap/baxter_gap_study_data_table.pdf.”.
3. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013; 12: 233–243. doi:10.1016/S1474-4422(13)70014-0 PMID: 23375965

4. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Offe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311–321. doi: 10.1056/NEJMoa1312889 PMID: 24450890

5. Salloway S, Sperling R, Fox NC, Blennow K, Klimk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322–333. doi:10.1056/NEJMoa1304839 PMID: 24450891

6. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472–1474. PMID:15377700

7. Relkin NR, Szabo P, Adamia B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30: 1728–1736. doi:10.1016/j.neurobiolaging.2007.12.021 PMID: 18294736

8. Bard F, Cannon C, Barbour RL, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Med 2000; 6: 916–919. PMID:10932230

9. Siemens ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010; 33: 67–73. doi:10.1097/ WNF.0b013e3181cb577a PMID: 20375655

10. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002; 52: 253–256. PMID: 12210803

11. Weksler ME, Szabo P, Relkin NL. IVIG therapy of mild to moderate Alzheimer's Disease (AD) patients showed significant benefits as measured by neuroimaging and neuropsychological testing in a Phase II, randomized, double-blind, placebo controlled clinical study. Gerontology 2010; 50: 449–449.

12. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013; 8: 36. doi: 10.1186/1750-1326-8-36 PMID: 24148220

13. Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013; 10: 70. doi: 10.1186/1742-2094-10-70 PMID: 23735288

14. Nimrernarv F, Ravelc JV. The anti-inflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204: 11–15. PMID: 17227911

15. Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945–949. PMID: 8105212

16. Ogata S, Shimizu C, Franco A, Touma R, Kanegaye JT, Choudhury BP, et al. Treatment response in kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin g. PLoS One 2013; 8: e81448. doi: 10.1371/journal.pone.0081448 PMID: 24324693

17. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 2010; 21: 1–14. doi:10.3233/JAD-2010-1414 PMID: 20182045

18. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid peptide beta. Autoimmun Rev 2008; 7: 415–420. doi: 10.1016/j.autrev.2008.03.007 PMID: 18558354

19. Balakrishnan K, Andrei-Selmer LC, Selmer T, Bacher M, Dodel R. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J Alzheimers Dis 2010; 20: 135–143. doi:10.3233/JAD-2010-1353 PMID: 20164596

20. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Abeta(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996; 271: 20631–20635. PMID: 8702810

21. McLean CA, Cherry RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860–866. PMID: 10589538

22. Walsh DM, Seilke DJ. A beta oligomers—a decade of discovery. J Neurochem 2007; 101: 1172–1184. PMID: 17286590

23. Dodel R, Balakrishnan K, Keyhani K, Deuster O, Neff F, Andrei-Selmer LC, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of...
Alzheimer's disease. J Neurosci 2011; 31: 5847–5854. doi: 10.1523/JNEUROSCI.4401-10.2011 PMID: 21490226

24. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Abeta1–42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 2010; 10: 115–119. doi: 10.1016/j.intimp.2009.10.005 PMID: 19840873

25. Klaver AC, Coffey MP, Smith LM, Loeffler DA. Comparison of ELISA measurements of anti-Abeta concentrations and percentages of specific binding to Abeta between unfraccionated intravenous immunoglobulin products and their purified anti-Abeta antibodies. Immunol Lett 2013; 154: 7–11. doi: 10.1016/j.imlet.2013.07.008 PMID: 23928186

26. O'Nuallain B, Williams AD, McWilliams-Koeppen HP, Acero L, Weber A, Ehrlich H, et al. Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol 2010; 30 Suppl 1: S37–42. doi: 10.1007/s10875-010-9413-6 PMID: 20405179

27. O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 2008; 47: 12254–12256. doi: 10.1021/bi801767k PMID: 18956886

28. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670–673. PMID: 16888140

29. Kasermann F, Boerema DJ, Ruegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012; 7: e37243. doi: 10.1371/journal.pone.0037243 PMID: 22675478

30. Christensen LL. Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997; 249: 153–164. PMID: 9212667

31. Richalet-Secordel PM, Rauffer-Bruyere N, Christensen LL, Ofenloch-Haehnle B, Seidel C, Van Regenmortel MH. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997; 249: 165–173. PMID: 9212668

32. Bee C, Abdiche YN, Pons J, Rajpal A. Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum. PLoS One 2013; 8: e80501. doi: 10.1371/journal.pone.0080501 PMID: 24232277

33. Sigmundsson K, Masson G, Rice R, Beauchemin N, Obrink B. Determination of active concentrations and association and dissociation rate constants of interacting biomolecules: an analytical solution to the theory for kinetic and mass transport limitations in biosensor technology and its experimental verification. Biochemistry 2002; 41: 8263–8276. PMID: 12081475

34. Lee C, Abdiche YN, Stone DM, Collier S, Lindquist KC, Pinkerton AC, et al. Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. PLoS One 2012; 7: e36261. doi: 10.1371/journal.pone.0036261 PMID: 22558410

35. Rogez-Florent T, Duhamel L, Goossens L, Six P, Drucbert AS, Depreux P, et al. Label-free characterization of carbonyl anhydrase-novel inhibitor interactions using surface plasmon resonance, isothermal titration calorimetry and fluorescence-based thermal shift assays. J Mol Recognit 2014; 27: 46–56. doi: 10.1002/jmr.2330 PMID: 24375583

36. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 2010; 227: 167–174. doi: 10.1016/j.jneuroim.2010.06.016 PMID: 20638735

37. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA. Measurement of anti-Abeta1–42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 2010; 187: 263–269. doi: 10.1016/j.jneuroimeth.2010.01.018 PMID: 20097229

38. Linman MJ, Taylor JD, Yu H, Chen X, Cheng Q. Surface plasmon resonance study of protein-carbohydrate interactions using biotinylated sialosides. Anal Chem 2008; 80: 4007–4013. doi: 10.1021/ac070566e PMID: 18461973

39. Stadtmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HU, et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009; 9: 4143–4153. doi: 10.1002/pmic.200800931 PMID: 19688751

40. Guhr T, Bloem J, Derksen NI, Wurzer M, Koenderman AH, Aalberse RC, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011; 6: e21246. doi: 10.1371/journal.pone.0021246 PMID: 21731683

41. Perdizova I, Deterding LJ, Cozma C, Tomer KB, Przybylski M. Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry. Glycobiology 2009; 19: 958–970. doi: 10.1093/glycob/cwp038 PMID: 19318519
42. Anumula KR. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc. J Immunol Methods 2012; 382: 167–176. doi: 10.1016/j.jim.2012.05.022 PMID: 22683540

43. Zagorski MG, Yang J, Shao H, Ma K, Zeng H, Hong A. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol 1999; 309: 189–204. PMID: 10507025

44. Stine WB Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003; 278: 11162–11162. PMID: 12499373

45. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 1989; 182: 319–326. PMID: 2610349

46. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, et al. Self-assembly of Abeta1–42 into globular neurotoxins. Biochemistry 2003; 42: 12749–12760. PMID: 14596589

47. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 2009; 284: 4230–4237. doi: 10.1074/jbc.M808591200 PMID: 19098006

48. Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006; 26: 6011–6018. PMID: 16738244

49. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yoshida N, et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 2003; 100: 6370–6375. PMID: 12750461

50. Yu L, Edalji R, Holman TF, Lopez AP, Labkovsky B, et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 2009; 48: 1870–1877. doi: 10.1021/bi802046n PMID: 19216516

51. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 2005; 33: 1087–1090. PMID: 16246051

52. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15: 349–357. doi: 10.1038/nn.3028 PMID: 22826176

53. Das C, Mainwarung R, Langone JJ. Separation of complexes containing protein A and IgG or Fc gamma fragments by high-performance liquid chromatography. Anal Biochem 1985; 145: 27–36. PMID: 3923863

54. Jendeberg L, Nilsson P, Larsson A, Denker P, Uhlen M, Nilsson B, et al. Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A. J Immunol Methods 1997; 201: 25–34. PMID: 9032407

55. Weinmann A, Nimmerjahn F, Reinhold VN, Paulson JC, Das C, Mainwarung R, et al. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2009; 449: 240–245. doi: 10.1016/j.neulet.2008.08.083 PMID: 18786612

56. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008; 8: 2858–2871. doi: 10.1002/ pmic.200700968 PMID: 18655055

57. Gagneux P, Cheriyan M, Hurtado-Ziola N, van der Linden EC, Anderson D, McClure H, et al. Human-specific regulation of alpha 2-6-linked sialic acids. J Biol Chem 2003; 278: 48245–48250. PMID: 14500706

58. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373–376. doi: 10.1126/ science.1154315 PMID: 18420934

59. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373–376. doi: 10.1126/ science.1154315 PMID: 18420934

60. Banks WA, Kastin AJ. Characterization of lectin-mediated brain uptake of HIV-1 GP120. J Neurosci Res 1998; 54: 522–529. PMID: 9822162

61. Dohgu S, Ryerse JS, Robinson SM, Banks WA. Human immunodeficiency virus-1 uses the mannose-6-phosphate receptor to cross the blood-brain barrier. PLoS One 2012; 7: e39565. doi: 10.1371/ journal.pone.0039565 PMID: 22761827
64. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A 2013; 110: 9868–9872. doi: 10.1073/pnas.1307864110 PMID: 23697368

65. Kingwell K. Alzheimer disease: bifunctional therapeutic antibody. Nat Rev Neurol 2011; 7: 359. doi: 10.1038/nrneurol.2011.95 PMID: 21691336

66. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014; 81: 49–60. doi: 10.1016/j.neuron.2013.10.061 PMID: 24411731